A morpholinocatechol compound (UK42620) with clonidine- and tyramine-like actions

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Neuropharmacology

Background:

• Understanding the mechanisms of adrenergic agents is crucial for cardiovascular drug development.
• Morpholinocatechol (UK42620) is a compound whose cardiovascular effects require detailed investigation.

Purpose of the Study:

• To elucidate the pharmacological actions of morpholinocatechol (UK42620) on cardiac function.
• To determine the specific adrenoceptor and neuronal pathways involved in UK42620's effects.

Main Methods:

• Isolated rat atria preparations were used to assess inotropic and chronotropic responses.
• Radioactive noradrenaline release was measured to quantify neurotransmitter dynamics.
• Pharmacological blockade with propranolol (beta-adrenoceptor antagonist) and desipramine (neuronal uptake blocker) was employed.

Main Results:

• UK42620 induced positive inotropic and chronotropic effects, alongside a significant increase in noradrenaline release.
• These actions mimicked tyramine and were inhibited by propranolol and desipramine.
• UK42620 demonstrated prejunctional alpha(2)-adrenoceptor activity, distinct from tyramine in the presence of desipramine, as shown by idazoxan antagonism of reduced radioactivity efflux.

Conclusions:

• UK42620 possesses both tyramine-like noradrenaline-releasing activity and prejunctional alpha(2)-adrenoceptor agonism.
• The compound's effects on cardiac function are mediated through the release of noradrenaline and interaction with alpha(2)-adrenoceptors.